PT1776958E - Inibidores peptídicos da via de transdução de sinal da jnk, permeáveis em células - Google Patents

Inibidores peptídicos da via de transdução de sinal da jnk, permeáveis em células Download PDF

Info

Publication number
PT1776958E
PT1776958E PT06019172T PT06019172T PT1776958E PT 1776958 E PT1776958 E PT 1776958E PT 06019172 T PT06019172 T PT 06019172T PT 06019172 T PT06019172 T PT 06019172T PT 1776958 E PT1776958 E PT 1776958E
Authority
PT
Portugal
Prior art keywords
cell
signal transduction
transduction pathway
peptide inhibitors
permeable peptide
Prior art date
Application number
PT06019172T
Other languages
English (en)
Portuguese (pt)
Inventor
Christophe Bonny
Original Assignee
Xigen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xigen Sa filed Critical Xigen Sa
Publication of PT1776958E publication Critical patent/PT1776958E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
PT06019172T 2002-06-07 2003-06-09 Inibidores peptídicos da via de transdução de sinal da jnk, permeáveis em células PT1776958E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/165,250 US20030108539A1 (en) 2000-02-14 2002-06-07 Cell-permeable peptide inhibitors of the JNK signal transduction pathway

Publications (1)

Publication Number Publication Date
PT1776958E true PT1776958E (pt) 2009-02-17

Family

ID=29732060

Family Applications (3)

Application Number Title Priority Date Filing Date
PT06019172T PT1776958E (pt) 2002-06-07 2003-06-09 Inibidores peptídicos da via de transdução de sinal da jnk, permeáveis em células
PT80213945T PT2060265E (pt) 2002-06-07 2003-06-09 Inibidores peptídicos da via de transdução de sinal da jnk, permeáveis em células
PT70163613T PT1911458E (pt) 2002-06-07 2003-06-09 Inibidores peptídicos da via de transdução de sinal da jnk, permeáveis em células

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT80213945T PT2060265E (pt) 2002-06-07 2003-06-09 Inibidores peptídicos da via de transdução de sinal da jnk, permeáveis em células
PT70163613T PT1911458E (pt) 2002-06-07 2003-06-09 Inibidores peptídicos da via de transdução de sinal da jnk, permeáveis em células

Country Status (14)

Country Link
US (1) US20030108539A1 (https=)
EP (7) EP1511507B1 (https=)
JP (2) JP4460445B2 (https=)
AT (2) ATE372125T1 (https=)
AU (1) AU2003274820B2 (https=)
CA (1) CA2488695C (https=)
CY (3) CY1108847T1 (https=)
DE (2) DE60316149D1 (https=)
DK (2) DK1776958T5 (https=)
ES (3) ES2439950T3 (https=)
HK (1) HK1207971A1 (https=)
PT (3) PT1776958E (https=)
SI (1) SI1776958T1 (https=)
WO (1) WO2003103698A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
EP1656951A1 (en) * 2004-11-12 2006-05-17 Xigen S.A. Conjugates with enhanced cell uptake activity
EP1661912A1 (en) * 2004-11-29 2006-05-31 Xigen S.A. Fusion protein comprising a BH3-domain of a BH3-only protein
US20060223807A1 (en) 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
WO2007031098A1 (en) * 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) * 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
EP2074138A4 (en) 2006-09-19 2009-12-30 Phylogica Ltd NEUROPROTECTIVE PEPTIDE AP-1 SIGNALING INHIBITORS AND USES THEREOF
KR20090115852A (ko) * 2007-01-19 2009-11-09 카이 파마슈티컬즈 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
EP2170932A4 (en) 2007-06-20 2012-10-10 Phylogica Ltd COMPOSITIONS AND APPLICATIONS THEREOF IN THE TREATMENT OF ACUTE ATOMIC SYNDROME (ARDS) AND ASSOCIATED CLINICAL ILLNESSES
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
CN102365093A (zh) * 2009-03-30 2012-02-29 参天制药株式会社 用于视网膜疾病的预防剂或治疗剂和使用JNK(c-Jun氨基末端激酶)抑制肽预防或治疗视网膜疾病的方法以及所述肽的用途
JP5457813B2 (ja) * 2009-12-16 2014-04-02 ルネサスエレクトロニクス株式会社 Ａｄｐｌｌ回路、半導体装置及び携帯情報機器
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
AU2010362444B2 (en) 2010-10-14 2015-08-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
EP2675409A4 (en) * 2011-02-18 2015-04-08 Otonomy Inc PREVENTING AND RESTORING MEDICAMENT-INDUCED OTOTOXICITY
MX2014006399A (es) * 2011-11-30 2015-04-10 Xigen Inflammation Ltd Uso de inhibidores de peptidos con celulas permeables de la via para transduccion de señal de jnk para el tratamiento de la queratoconjuntivitis seca.
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206426A1 (en) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
ES2870085T3 (es) 2013-06-26 2021-10-26 Xigen Inflammation Ltd Inhibidores peptídicos permeables a células de la ruta de transducción de señales de JNK para el tratamiento de la cistitis
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
GB201719520D0 (en) * 2017-11-24 2018-01-10 Univ College Cardiff Consultants Ltd Neuroprotectvie peptide
CN109182250A (zh) * 2018-09-30 2019-01-11 山东省立医院 一种小鼠耳蜗毛细胞培养方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US817457A (en) * 1906-01-18 1906-04-10 Kelley M Turner Head band or support for telephone-receivers.
US1447969A (en) * 1922-05-12 1923-03-13 Brandes Inc C Telephone head set
US4048453A (en) * 1976-02-11 1977-09-13 Gustave Seidel Telephone handset support device
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
DE4005783A1 (de) * 1990-02-23 1991-09-05 Andreas Suckert Kopfhalterung fuer telefonhoerer
CA2135642C (en) * 1992-08-21 1999-12-14 James G. Barsoum Tat-derived transport polypeptides
KR950703640A (ko) 1992-10-09 1995-09-20 가일 케이,나우톤. 간 보존 세포(liver reserve cells)
WO1996034093A1 (en) * 1995-04-25 1996-10-31 Baxter International Inc. Composition containing collagenase and chymopapain for isolating hepatocytes and pancreatic islet cells
BR9610058A (pt) 1995-07-28 1999-07-27 Marie Curie Cancer Care Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células
US5689558A (en) * 1996-03-25 1997-11-18 Osgood; Alan G. Telephone handset holder
US5880261A (en) * 1997-04-03 1999-03-09 Waeber; Gerard Transcription factor Islet-Brain 1 (IB1)
US5828749A (en) * 1997-04-04 1998-10-27 Brodskiy; Arkadiy Phone holder kit
US6043083A (en) * 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
EP0897002A3 (en) * 1997-08-14 2001-10-04 Smithkline Beecham Plc U62317, a protein having a JNK-binding domain
EP0947524A1 (en) * 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
WO1999058561A1 (fr) * 1998-05-14 1999-11-18 Pasteur Merieux Serums & Vaccins Mimotopes du virus de l'hepatite c
CA2328457A1 (en) * 1998-06-20 1999-12-29 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
WO2000018407A1 (en) * 1998-09-25 2000-04-06 Cephalon, Inc. Methods for preventing/treating damage to sensory hair cells and cochlear neurons
US6610820B1 (en) * 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20010046489A1 (en) * 1999-12-06 2001-11-29 Habener Joel E. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US20040014212A1 (en) * 2000-10-17 2004-01-22 Elliott Robert Bartlett Preparation and xenotransplantation or porcine islets
JP4234999B2 (ja) * 2001-04-06 2009-03-04 トマス ジェファソン ユニバーシティ 治療標的としてのｈｉｖ−１ｖｉｆタンパク質の多量体形成
DE10117281A1 (de) * 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptid zur Diagnose und Therapie der Alzheimer-Demenz

Also Published As

Publication number Publication date
CA2488695A1 (en) 2003-12-18
EP1511507A1 (en) 2005-03-09
DK1776958T5 (da) 2013-10-21
ES2439950T3 (es) 2014-01-27
EP1970070A3 (en) 2010-06-02
SI1776958T1 (sl) 2009-06-30
ATE372125T1 (de) 2007-09-15
EP1776958B9 (en) 2013-08-14
JP2010053136A (ja) 2010-03-11
EP2060265B1 (en) 2013-10-09
EP1776958B1 (en) 2008-12-17
DE60316149D1 (de) 2007-10-18
HK1207971A1 (en) 2016-02-19
EP2845603A1 (en) 2015-03-11
PT1911458E (pt) 2014-05-07
HK1098961A1 (en) 2007-08-03
EP2532357A3 (en) 2013-08-14
EP2532357A2 (en) 2012-12-12
PT2060265E (pt) 2013-11-27
DK1776958T3 (da) 2009-04-06
CA2488695C (en) 2011-12-20
EP1776958A3 (en) 2007-12-26
HK1111635A1 (en) 2008-08-15
ES2473274T9 (es) 2015-02-26
ATE417623T1 (de) 2009-01-15
JP2006501165A (ja) 2006-01-12
JP4460445B2 (ja) 2010-05-12
DK1911458T3 (da) 2014-04-07
CY1114715T1 (el) 2016-10-05
EP1970070A2 (en) 2008-09-17
ES2319454T9 (es) 2013-11-25
EP1911458B1 (en) 2014-03-19
WO2003103698A1 (en) 2003-12-18
US20030108539A1 (en) 2003-06-12
ES2473274T3 (es) 2014-07-04
EP2060265A3 (en) 2010-06-02
AU2003274820A1 (en) 2003-12-22
CY1108847T1 (el) 2014-07-02
EP2060265A2 (en) 2009-05-20
DK1911458T5 (da) 2015-01-05
EP1911458B9 (en) 2014-11-19
EP1511507B1 (en) 2007-09-05
AU2003274820B2 (en) 2009-01-08
CY1115331T1 (el) 2017-01-04
EP1911458A3 (en) 2008-07-02
EP1776958A2 (en) 2007-04-25
DE60325429D1 (de) 2009-01-29
ES2319454T3 (es) 2009-05-07
EP1911458A2 (en) 2008-04-16

Similar Documents

Publication Publication Date Title
PT1911458E (pt) Inibidores peptídicos da via de transdução de sinal da jnk, permeáveis em células
PT1303600E (pt) Inibidores peptídicos de permeabilidade celular da via de transdução do sinal de jnk
EP1501532A4 (en) PEPTIDE INHIBITORS OF PROTEIN KINASE C
AU2003249920A1 (en) Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
IL237984A0 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway
NO20005637L (no) Hybridprotein for å inhibere degranulasjon av mastocyter og anvendelsen derav
DK1495128T3 (da) Forstærket proteinekspression i Bacillus
WO2003057725A3 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway
EP1696943A4 (en) PEPTIDES DIASTEREOMERS USEFUL AS INHIBITORS OF MEMBRANE PROTEIN ASSEMBLY
AU2003282338A8 (en) Determination of protein function
WO2005044244A3 (de) Verwendung von mrp4-inhibitoren zur behandlung und/oder prophylaxe kardiovaskulärer erkrankungen
MY142798A (en) Methods for preventing glyconoylation of proteins
WO2003087145A3 (en) Purified polypeptides involved in quorum sensing
HK1074398A (en) Peptide inhibitors of protein kinase c
IL150944A0 (en) Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics